Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There are 2 clinical trials
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Description: ESRD will be defined as need for chronic dialysis or renal transplantation.
Measure: Time to ESRD or death Time: 5 to 9 yearsDescription: Quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF)
Measure: Quality of life (KDQoL-SF) Time: 5 to 9 yearsDescription: Time until doubling of serum creatinine
Measure: Time until doubling of serum creatinine Time: 5 to 9 yearsDescription: The risk of a CHF hospitalization will be based on the participant-time data, specifically, the number of events per years.
Measure: Incidence of congestive heart failure hospitalization (CHF) Time: 5 to 9 yearsDescription: The risk of a MACE event will be based on participant-time data, specifically, the number of events per participant years.
Measure: Incidence of a three-point MACE Time: 5 to 9 yearsDescription: The risk of a PVD event will be based on participant-time data, specifically, the number of events per participant years.
Measure: Incidence of a peripheral vascular disease (PVD) Time: 5 to 9 yearsDescription: Percentage of participants with 50% reduction in UACR from baseline
Measure: Percentage of participants with 50% reduction in UACR from baseline Time: 5 to 9 yearsDescription: Rate of change in eGFR per year during the study period.
Measure: Rate of change in eGFR per year during the study period Time: 5 to 9 yearsA Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
Description: Change compared to placebo
Measure: Urine albumin:creatinine ratio (UACR) Time: Baseline to Day 169 (24 weeks)Description: To assess the number Treatment Emergent Adverse events (TEAEs), Serious Adverse Events (SAEs), Treatment Emergent Adverse Events of Special Interest (AESIs)
Measure: Safety and Tolerability by assessment of adverse events Time: Visit 1 (Screening) to Day 230 (End of Study)Description: MEDI3506 serum PK concentrations throughout the study
Measure: PK profile of MEDI3506 Time: Day 1 to Day 230Description: Anti-drug antibodies (ADAs) incidence throughout the study
Measure: Immunogenicity of MEDI3506 Time: Day 1 to Day 230Description: Proportion of subjects with > 30%, 40% or 50% reduction
Measure: UACR Time: At Day 169, baseline to Day 85 (12 weeks) or Day 85 to Day 169Description: To assess systolic and diastolic blood pressure, heart rate, respiratory rate, temperature, 12-lead electrocardiogram, echocardiogram and physical exam
Measure: Safety and tolerability by assessment of vital signs Time: Visit 1(Screening) to End of studyDescription: To assess hematology, serum chemistry, urinalysis
Measure: Safety and tolerability by clinical laboratory evaluations Time: Visit 1(Screening) to End of studyAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports